Physician profile
Patrick G Goodman
NPI 1639392558
$6,613.90
in general payments reported to CMS, 2019-2025
35 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $823 · 2021: $1,014 · 2022: $906 · 2023: $772 · 2024: $1,157 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,675.54 | 2019-2025 | Superion Indirect Decompression System, General - Pain Management, General - Therapies |
| Collegium Pharmaceutical, INC. | $741.32 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $738.14 | 2021-2025 | |
| Pfizer INC. | $396.20 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $371.95 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.10 | 2021-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $326.34 | 2019-2025 | Ajovy, Austedo |
| Lilly USA, LLC | $254.04 | 2019-2023 | Reyvow, Emgality |
| Amgen INC. | $248.48 | 2019-2022 | |
| Almatica Pharma LLC | $193.34 | 2021-2023 | Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $127.93 | 2019-2020 | |
| Eisai INC. | $120.71 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $93.37 | 2021 | |
| Pacira Therapeutics, INC. | $85.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $84.55 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $77.94 | 2022 | |
| Forte Bio-Pharma LLC | $74.58 | 2020 | |
| Averitas Pharma INC. | $66.23 | 2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $62.92 | 2024-2025 | |
| Allergan, INC. | $61.91 | 2020 | |
| Redhill Biopharma INC. | $61.14 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $58.53 | 2022-2024 | Quviviq |
| Sentynl Therapeutics, INC. | $53.79 | 2019 | |
| Horizon Therapeutics Plc | $46.68 | 2020-2023 | Krystexxa |
| Depuy Synthes Sales INC. | $43.80 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $37.40 | 2020 | |
| Shionogi INC | $30.09 | 2019 | |
| Nalu Medical, INC. | $28.15 | 2022 | |
| Ibsa Pharma INC. | $28.02 | 2023-2024 | Tirosint, Licart, Licart |
| Biodelivery Sciences International, INC. | $27.81 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $14.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.37 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $13.72 | 2022 | |
| Alfasigma USA, INC. | $12.81 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.